Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib

Although sorafenib is expected to have a chemopreventive effect on hepatocellular carcinoma (HCC) recurrence, there are limitations to its use because of adverse effects, including effects on liver function. We have reported that the iron chelator, deferoxamine can prevent liver fibrosis and preneop...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Naoki, Yamasaki, Takahiro, Takami, Taro, Uchida, Koichi, Fujisawa, Koichi, Matsumoto, Toshihiko, Saeki, Issei, Terai, Shuji, Sakaida, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: the Society for Free Radical Research Japan 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865599/
https://www.ncbi.nlm.nih.gov/pubmed/27257345
http://dx.doi.org/10.3164/jcbn.15-127

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4865599/
https://www.ncbi.nlm.nih.gov/pubmed/27257345
http://dx.doi.org/10.3164/jcbn.15-127

Ejemplares similares